ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - Generic Drug Details

What are the generic sources for albuterol sulfate; ipratropium bromide and what is the scope of patent protection?

Albuterol sulfate; ipratropium bromide is the generic ingredient in four branded drugs marketed by Boehringer Ingelheim, Aiping Pharm Inc, Apotex Inc, Cipla, Luoxin Aurovitas, Nephron, Ritedose Corp, Sun Pharm, Teva Pharms, Watson Labs Teva, and Pharmobedient, and is included in twelve NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Albuterol sulfate; ipratropium bromide has seventy-two patent family members in thirty-five countries.

Fifteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

International Patents:	72
US Patents:	4
Tradenames:	4
Applicants:	11
NDAs:	12
Finished Product Suppliers / Packagers:	15
Clinical Trials:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
DailyMed Link:	ALBUTEROL SULFATE; IPRATROPIUM BROMIDE at DailyMed

Recent Clinical Trials for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
James J. Peters Veterans Affairs Medical Center	Phase 2
University of Texas Southwestern Medical Center	Phase 4
Dey	Phase 3

See all ALBUTEROL SULFATE; IPRATROPIUM BROMIDE clinical trials

Generic filers with tentative approvals for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 0.083% BASE;0.017%	SOLUTION;INHALATION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Drug Class	Anticholinergic beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

A07DA	Antipropulsives
A07D	ANTIPROPULSIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

N02AA	Natural opium alkaloids
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

R01AX	Other nasal preparations
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BB	Anticholinergics
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

Paragraph IV (Patent) Challenges for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COMBIVENT RESPIMAT	Inhalation Aerosol	albuterol sulfate; ipratropium bromide	100 mcg/20 mcg per actuation	021747	1	2023-03-30

US Patents and Regulatory Information for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE	albuterol sulfate; ipratropium bromide	SOLUTION;INHALATION	207875-001	Aug 7, 2017	AN	RX	No	No
Boehringer Ingelheim	COMBIVENT	albuterol sulfate; ipratropium bromide	AEROSOL, METERED;INHALATION	020291-001	Oct 24, 1996		DISCN	No	No
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes	7,837,235		Y		Y
Teva Pharms	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE	albuterol sulfate; ipratropium bromide	SOLUTION;INHALATION	076724-001	Dec 31, 2007		DISCN	No	No
Watson Labs Teva	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE	albuterol sulfate; ipratropium bromide	SOLUTION;INHALATION	077063-001	Dec 31, 2007		DISCN	No	No

Expired US Patents for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011	6,977,042
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011	7,988,001
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011	6,453,795
Boehringer Ingelheim	COMBIVENT	albuterol sulfate; ipratropium bromide	AEROSOL, METERED;INHALATION	020291-001	Oct 24, 1996	5,603,918
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011	6,149,054

International Patents for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

Country	Patent Number	Title	Estimated Expiration
Colombia	5700802	DISPOSITIVO PARA SUJETAR UN ELEMENTO PARA FLUIDOS
Israel	167102	BLOCKING DEVICE FOR A SPRUNG LOCK WITH A SPRING OPERATION
Japan	2007517646
Germany	502004005733
European Patent Office	1539368	Appareil avec dispositif de blocage pour un mécanisme tendeur à blocage pourvu d'un mécanisme à ressort (Apparatus with blocking device for a sprung lock with a spring mechanism)

Market Dynamics and Financial Trajectory for Albuterol Sulfate and Ipratropium Bromide

Last updated: February 20, 2026

What are the key market drivers for albuterol sulfate and ipratropium bromide?

Albuterol sulfate and ipratropium bromide are longstanding drugs used primarily for respiratory conditions. Albuterol sulfate is a short-acting beta-agonist (SABA), indicated mainly for bronchospasm associated with asthma and COPD. Ipratropium bromide is a bronchodilator classified as an anticholinergic agent, used in COPD and sometimes asthma. The market expansion depends on disease prevalence, treatment guidelines, and formulation innovations.

Key drivers include:

• Rising prevalence of respiratory diseases, especially COPD and asthma.
• Increased adoption of inhaled therapies aligned with global guidelines.
• Growing geriatric population, susceptible to respiratory illnesses.
• Patent expirations prompting generic competition, impacting margins.
• Focus on delivering multi-drug inhaler formulations for improved compliance.

How does disease prevalence influence market size?

Respiratory diseases are among the most common chronic illnesses worldwide. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) reports over 200 million COPD cases globally as of 2020. Asthma affects approximately 262 million individuals globally, with increased incidence in developing countries. These numbers translate into consistent demand for inhaled bronchodilators with a projected compounded annual growth rate (CAGR) ranging from 3% to 5% over the next decade.

What are recent regulatory and patent trends affecting these drugs?

• Patent expirations: Several patents for branded formulations expired or are nearing expiry. For example, the patents on brand-name albuterol products in the U.S. expired around 2018–2020. This opens pathways for generics, intensifying price competition.
• Regulatory approvals: New formulations, such as inhalers with added drug combinations or device improvements, have received FDA approval. These innovations aim to improve delivery efficiency and patient adherence.

What are the competitive landscape features?

The market is highly competitive with multiple generic manufacturers, including Mylan, Teva, and Sandoz. The patent expirations have led to increased market share for generics, which comprise approximately 70% of sales in North America. Innovator companies are developing combination inhalers containing albuterol and ipratropium bromide to secure premium pricing and extend product lifecycle.

How does geographic variation affect revenue streams?

North America holds approximately 45% of the global market, driven by high COPD and asthma prevalence, favorable pricing, and advanced healthcare infrastructure. Europe accounts for about 25%, with rising demand in countries like Germany and the UK. Asia-Pacific presents high growth potential with markets in China, India, and Southeast Asia expanding due to increasing air pollution and urbanization, despite lower current market penetration.

What are the implications of current formulations and innovations?

• Delivery devices: Turbuhaler, metered-dose inhalers (MDIs), and dry powder inhalers (DPIs) dominate. Innovations aim to improve spray consistency, reduce technique errors, and enhance patient compliance.
• Combination therapies: Fixed-dose combinations (FDCs), such as albuterol-ipratropium inhalers, are gaining acceptance for simplifying regimens.
• Biologic and alternative modalities: Although not directly related, ongoing development of biologics for severe respiratory conditions poses long-term competitive pressure.

What is the financial outlook?

Revenue estimates project the global inhaled bronchodilator market value at approximately USD 6.8 billion in 2021, with a CAGR of 4% expected through 2030. Generics and biosimilars could erode up to 20% of branded revenues by 2025. Meanwhile, innovative formulations and combination products are expected to account for 15% of sales growth in the same period.

The impact of market entry by biosimilars and increased price sensitivity will compress revenue margins, emphasizing the need for cost-effective production and differentiated formulations.

What risks and opportunities shape the future?

Risks:

• Competitive pressure from generics and biosimilars.
• Pricing reforms in major markets, particularly under Medicare and Medicaid.
• Regulatory hurdles for new delivery devices.

Opportunities:

• Expansion into high-growth markets in Asia.
• Development of combination inhalers with improved device ergonomics.
• Adoption of digital inhaler technologies for adherence tracking.

Key Takeaways

• The global market for albuterol sulfate and ipratropium bromide is driven by respiratory disease prevalence.
• Patent expirations catalyze increased generic competition, pressuring prices.
• North America dominates, but Asia-Pacific offers significant growth potential.
• Innovation in inhaler device technology and combination therapies sustains profitability.
• Market revenue is projected to grow at 4% annually until 2030, with a shift toward biosimilars and cost containment strategies.

FAQs

1. How will biosimilars influence the market for albuterol and ipratropium bromide?
While biosimilars are more relevant for biologic therapies, near-market generic inhalers will challenge branded products. Price competition will enhance affordability but may reduce profit margins.

2. What regulatory changes could impact product approvals?
Regulations encouraging device standardization and approval pathways for combination inhalers could accelerate product launches and influence market share distribution.

3. Are there emerging innovations in inhaler technology?
Yes, digital inhalers with adherence tracking and connected devices are being integrated into treatment regimens, offering data for personalized therapy.

4. How significant is the impact of the aging population?
Aging populations increase demand, especially in North America and Europe, leading to higher sales of inhalers for chronic respiratory diseases.

5. Which markets are the most promising for expansion?
China, India, and Southeast Asia are promising due to rising disease burden and nascent healthcare infrastructure for respiratory conditions.

References

1. Global Initiative for Chronic Obstructive Lung Disease. (2020). GOLD 2020 Report. Retrieved from https://goldcopd.org/gold-reports/
2. MarketWatch. (2022). Inhalers and Respiratory Devices Market Size, Share & Trends Analysis. Retrieved from https://www.marketwatch.com/
3. IQVIA. (2021). Global Use of Medicines.
4. Bloomberg. (2023). Trends in generic drug markets and patent expirations.
5. U.S. Food and Drug Administration. (2022). Inhalation Drug Approvals.